Eupraxia Pharmaceuticals Inc. (EPRX.TO) Research

Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.

Market snapshot

Symbol
EPRX.TO
Price
$9.06
Day change
-1.20%
Market cap
$229.8M
P/E ratio
-6.09x
52-week range
5.83-12.86
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cybin Inc. (CYBN.NE)
  • Medical Facilities Corporation (DR.TO)
  • Fennec Pharmaceuticals Inc. (FRX.TO)
  • Helix BioPharma Corp. (HBP.TO)
  • Medicenna Therapeutics Corp. (MDNA.TO)
  • NervGen Pharma Corp. (NGEN.V)
  • OrganiGram Holdings Inc. (OGI.TO)
  • Profound Medical Corp. (PRN.TO)

Open Eupraxia Pharmaceuticals Inc. (EPRX.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.